| UHC UMR Medical and Drug | Synagis® (Palivizumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Alpha1-Proteinase Inhibitors – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Brineura® (Cerliponase Alfa) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Buprenorphine (Brixadi® & Sublocade®) - Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Hereditary Angioedema (HAE), Treatment and Prophylaxis – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Ilaris® (Canakinumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Intracanalicular and Intravitreal Corticosteroid Implants – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Krystexxa® (Pegloticase) – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Self-Administered Medications – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC Surest Medical and Drug | Synagis® (Palivizumab) – Commercial Medical Benefit Drug Policy | 2025-11-01 |